EIC Accelerator

Iktos is a French company specializing in artificial intelligence-driven solutions for medicinal chemistry and new drug discovery. It offers SaaS platforms Makya™ for generative drug design and Spaya™ for retrosynthesis, accelerating pharmaceutical R&D. Iktos also develops AI-driven synthesis automation platform Iktos Robotics and has its own drug pipeline targeting oncology and autoimmune diseases.

Hummink is a company specializing in additive manufacturing technology, focusing on nano-printing solutions that enable precise design and manufacturing at the nanoscale. Founded in 2020 in Paris by Amin M'barki, Pascal Boncenne, Lydéric Bocquet, Alessandro Siria, and Antoine Nigues, Hummink utilizes a patented technology that integrates a nanometric pen with an oscillating microresonator. This innovative approach allows for the capillary deposition of various liquids, equipping clients in the semiconductor and molecular diagnostic industries with the capability to create large objects while maintaining exceptional resolution and precision on substrates ranging from millimetric to centimetric scales.

Hummink is a company specializing in additive manufacturing technology, focusing on nano-printing solutions that enable precise design and manufacturing at the nanoscale. Founded in 2020 in Paris by Amin M'barki, Pascal Boncenne, Lydéric Bocquet, Alessandro Siria, and Antoine Nigues, Hummink utilizes a patented technology that integrates a nanometric pen with an oscillating microresonator. This innovative approach allows for the capillary deposition of various liquids, equipping clients in the semiconductor and molecular diagnostic industries with the capability to create large objects while maintaining exceptional resolution and precision on substrates ranging from millimetric to centimetric scales.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

Omini is a biotechnology company based in Saint Mandé, France, founded in 2019. It specializes in the development of portable and multipurpose bio-sensing devices designed for immediate blood testing. Omini's biosensor platform enables the simultaneous detection of multiple biomarkers, providing personalized blood biomarker data that can be utilized to customize therapies and prevent acute crises in patients with chronic conditions. By leveraging multiplex electrochemical biosensor technology, the company offers affordable and accurate monitoring solutions that facilitate decentralized testing and at-home monitoring, ultimately helping to alleviate the burden on healthcare systems. Omini primarily serves general practitioners, aiming to enhance patient care through innovative diagnostic tools.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

Laclarée is a French company based in Lyon, founded in 2016, that specializes in developing adaptive eyeglasses specifically designed to correct presbyopia. The company's innovative product incorporates patented fluid technology, allowing the eyeglasses to automatically adjust to different viewing distances in real-time. This advancement aims to address the needs of individuals aged 45 and older who are often dissatisfied with traditional vision correction solutions, such as progressive lenses or the use of multiple pairs of glasses. By combining adaptive lens technology with refractive correction capabilities for conditions like astigmatism, myopia, and hyperopia, Laclarée seeks to provide a more effective solution for clear vision across various distances.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

Omini is a biotechnology company based in Saint Mandé, France, founded in 2019. It specializes in the development of portable and multipurpose bio-sensing devices designed for immediate blood testing. Omini's biosensor platform enables the simultaneous detection of multiple biomarkers, providing personalized blood biomarker data that can be utilized to customize therapies and prevent acute crises in patients with chronic conditions. By leveraging multiplex electrochemical biosensor technology, the company offers affordable and accurate monitoring solutions that facilitate decentralized testing and at-home monitoring, ultimately helping to alleviate the burden on healthcare systems. Omini primarily serves general practitioners, aiming to enhance patient care through innovative diagnostic tools.

Atamyo Therapeutics is a biotechnology company based in Paris, France, established in 2020 by Stephane Degove and Isabelle Richard. The company is dedicated to developing innovative gene therapies aimed at treating neuromuscular diseases, particularly muscular dystrophies. Atamyo focuses on creating safer and more effective gene therapies by exploring novel approaches for gene replacement. Its research includes the development of specialized delivery systems designed to minimize side effects and enhance the restoration of normal physiological function in patients suffering from these challenging conditions. Through its advancements in gene therapy, Atamyo Therapeutics aims to improve the quality of life for individuals affected by neuromuscular disorders.

Womed SAS, founded in 2018, is a medical device company that originated from research at Professor Garric's biopolymer lab at the University of Montpellier, France. The company focuses on addressing unmet medical needs in gynecologic surgery, particularly intrauterine adhesions, which can impact fertility and pregnancy. Womed develops insertable devices designed to act as mechanical barriers against adhesions, protecting the uterine cavity. These devices are engineered to break up, dissolve, and be naturally discharged without requiring intervention from healthcare professionals, thereby helping women reduce or prevent recurrent intrauterine adhesion formation and miscarriage.

Defacto Technologies SA is a chip design software company specializing in enhancing the design-for-test (DFT) process and improving the testability of integrated circuits and systems on chip (SoCs). Founded in 2003 and headquartered in Moirans, France, with an additional office in Sunnyvale, California, the company offers a comprehensive suite of electronic design automation (EDA) tools. This includes HiDFT-SIGNOFF, which facilitates scan logic insertion at the register transfer level (RTL), and HiDFT-STAR, a customizable tool for editing RTL designs of IP cores and SoC blocks. Defacto Technologies also provides RTL testability debug and signoff, as well as RTL DFT verification solutions. Its software serves various industries, including automotive, mobile, virtual reality, and artificial intelligence, enabling clients to develop advanced SoCs with enhanced functionality and lower power consumption. The company has established a global presence with sales offices across China, Japan, Taiwan, South Korea, Singapore, Israel, and Europe.

Toopi Organics is a biotechnology company based in Langon, France, established in 2019. It develops microbiological and agricultural technologies to transform human urine into fertilizers and biostimulants for agriculture. The company collects and upcycles human urine, depollutes and enriches it with microorganisms to provide natural, economical, and efficient alternatives to chemical fertilizers. Its products include Arbop and Vitip, which support plant growth and crop health, offering farming communities an environmentally conscious option for nutrient supply.